Pathways to melanoma development: Lessons from the mouse

Journal of Investigative Dermatology

Volumn 119, Issue 4, 2002, Pages 783-792

  Walker, Graeme J ^a   Hayward, Nicholas K ^a  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

Knockout mice; Melanoma; Transgenic mice

Indexed keywords

ARF PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; ONCOPROTEIN; PROTEIN INK4A; RAS PROTEIN; UNCLASSIFIED DRUG;

ANIMAL MODEL; CARCINOGENESIS; DISEASE MODEL; DNA MODIFICATION; ENZYME ACTIVATION; GENE LOCUS; GENE MUTATION; GENETIC CODE; MELANOMA; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; ULTRAVIOLET RADIATION;

EID: 0036430068     PISSN: 0022202X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1747.2002.00217.x     Document Type: Review

References (96)

1. Ali S, DeCaprio J: Cellular transformation by SV40 large T antigen: Interaction with host proteins. Semin Cancer Biol 11:15-23, 2001
2. Atkas H, Cai H, Cooper GM: Ras links factor signalling to the cell cycle machinery via regulation of cyclin D1 and Cdk inhibitor p27. Mol Cell Biol 17:3850-3857, 1997
3. Bahuau M, Vidaud D, Jenkins RB, et al: Germ-line deletion involving the INK4 locus in familial proneness to melanoma and nervous system tumors. Cancer Res 58:2298-2303, 1998
4. Bardeesy N, Bastian B, Hezel A, Pinkel D, DePinho R, Chin L: Dual inactivation of RB and p53 pathways in RAS-induced melanomas. Mol Cell Biol 21:2144-2153, 2001
5. ARF links the tumour suppressors RB and p53. Nature 395:124-125, 1998
6. Beermann F, Hunziker A, Foletti A: Transgenic models for tumors of melanocytes and retinal pigment epithelium. Pigment Cell Res 12:71-80, 1999
7. Bradl M, Klein-Szanto A, Porter S, Mintz B: Malignant melanoma in transgenic mice. Proc Natl Acad Sci USA 88:164-168, 1991
8. Broome Powell M, Hyman P, Bell OD, et al: Hyperpigmentation and melanocytic dysplasia in transgenic mice expressing human T24 Hras gene regulated by a mouse tyrosinase promoter. Mol Carcinogen 12:82-90, 1995
9. Broome-Powell M, Gause P, Hyman P, Gregus J, Lluria-Prevatt M, Nagle R, Bowden GT: Induction of melanoma in TPras transgenic mice. Carcinogenesis 20:1747-1753, 1999
10. Cantley LC, Neel BG: New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA 96:4240-4245, 1999
11. ARF act in overlapping pathways in cellular immortalisation. Nature Cell Biol 2:148-155, 2000
12. Castellano M, Pollock PM, Walters MK, et al: CDKN2A/p16 is inactivated in most melanoma cell lines. Cancer Res 57:4868-4875, 1997
13. Chen S, Zhu H, Wetzel WJ, Philbert MA: Spontaneous melanocytosis in transgenic mice. J Invest Dermatol 106:1145-1151, 1996
14. Chin L, Pomerantz J, Polsky D, et al: Cooperative effects of INK4a and ras in melanoma susceptibility in vivo. Genes Dev 11:2822-2834, 1997
15. Chin L, Pomerantz J, DePinho R: The INK4a/ARF tumor suppressor: One gene-two products-two pathways. Trends Biochem Sci 23:291-296, 1998
16. Chin L, Tam A, Pomerantz J, et al: Essential role for oncogenic Ras in tumour maintenance. Nature 400:468-472, 2000
17. Di Cristofano A, Pesce B, Cordon-Cardo C, Pandolfi P: Pten is essential for embryonic development and tumour suppression. Nat Genet 19:348-355, 1998
18. Kip1 cooperate in prostate cancer tumor suppression in mouse. Nat Genet 27:222-224, 2001
19. DiLiberti JH: Inherited macrocephaly-hamartoma syndromes. Am J Med Genet 79:284-290, 1998
20. Dracopoli NC, Fountain JW: CDKN2A mutations in melanoma. Cancer Surveys 26:115-132, 1996
21. Easty D, Bennett D: Protein tyrosine kinases in malignant melanoma. Melanoma Res 10:401-411, 2000
22. van Elsas A, Zerp S, van der Flier S, et al: N-ras oncogene point mutations induced by sun exposure in primary cutaneous melanoma. Am J Pathol 149:883-893, 1996
23. Erickson C: From the crest to the periphery. Control of pigment cell migration and lineage segregation. Pigment Cell Res 6:336-347, 1993
24. Eymin B, Karayan L, Seite P, Brambilla C, Brambilla E, Larsen CJ, Gazzeri S: Human ARF binds E2F1 and inhibits its transcriptional activity. Oncogene 20:1033-1041, 2001
25. KIP1 mediate two separate pathways to collaboratively suppress pituitary tumorigenesis. Genes Dev 12:2899-2911, 1998
26. Gallagher C, Canfield P, Greenhoak G, Reeve V: Characterization and histogenesis of tumors in the hairless mouse produced by low-dosage incremental ultraviolet radiation. J Invest Dermatol 83:169-174, 1984
27. Ganss R, Montoliu L, Monaghan AP, Schutz G: A cell-specific enhancer far upstream of the mouse tyrosinase gene confers high level and copy number-related expression in transgenic mice. EMBO J 13:3083-3093, 1994
28. He J, Allen JR, Collins VP, Allalunis-Turner MJ, Godbout R, Day RS 3rd, James CD: CDK4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cells lines. Cancer Res 54:5804-5807, 1994
29. Hemesath T, Price ER, Takemoto C, Badalian T, Fisher D: MAP kinase links the transcription factor microphthalmia to c-kit signalling in melanocytes. Nature 391:298-301, 1998
30. Hirobe T: Structure and function of melanocytes: Microscopic morphology and cell biology of mouse melanocytes in the epidermis and hair follicle. Histol Histopathol 10:223-237, 1995
31. Hu N, Gutsmann A, Herbert DC, Bradley A, Lee WH, Lee EY: Heterozygous Rb-1 delta 20/+mice are predisposed to tumors of the pituitary gland with a nearly complete penetrance. Oncogene 4:1021-1027, 1994
32. Hu W, Bellone CJ, Baldassare JJ: RhoA stimulates p27 (Kip) degradation through its regulation of cyclin E/CDK2 activity. J Biol Chem 274:3396-3401, 1999
33. Hunter T: Oncoprotein networks. Cell 88:333-346, 1997
34. Hussussian CJ, Struewing JP, Goldstein AM, et al: Germline p16 mutations in familial melanoma. Nat Genet 8:15-21, 1994
35. Iwamoto T, Takahashi M, Ito M, et al: Aberrant melanogenesis and melanocytic tumour development in transgenic mice that carry a metallothionein/ret fusion gene. EMBO J 10:3167-3175, 1991
36. Jacks T, Fazeli A, Schmitt EM, Bronson RT, Goodell MA, Weinberg RA: Effects of an Rb mutation in the mouse. Nature 359:295-300, 1992
37. Kamb A, Shattuck-Eidens D, Eeles R, et al: Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat Genet 8:23-26, 1994
38. ARF. Cell 91:649-659, 1997
39. Kato M, Takahashi M, Akhand AA, et al: Transgenic mouse model for skin malignant melanoma. Oncogene 17:1885-1888, 1998
40. Kato M, Liu W, Akhand AA, Hossain K, Takeda K, Takahashi M, Nakashima I: Ultraviolet radiation induces both full activation of ret kinase and malignant melanocytic tumor promotion in RFP-RET-transgenic mice. Invest Dermatol 115:1157-1158, 2000
41. Kelsall SR, Mintz B: Metastatic cutaneous melanoma promoted by ultraviolet radiation in mice with transgene-initiated low melanoma susceptibility. Cancer Res 58:4061-4065, 1998
42. Klein-Szanto A, Bradl M, Porter S, Mintz B: Melanosis and associated tumors in transgenic mice. Proc Natl Acad Sci USA 88:169-173, 1991
43. Klein-Szanto AJ, Silvers WK, Mintz B: Ultraviolet radiation-induced malignant skin melanoma in melanoma-susceptible transgenic mice. Cancer Res 54:4569-4572, 1994
44. Ink4a confers susceptibility to metastatic melanoma in mice. Nature 413:83-86, 2001
45. Kumar R, Sauroja I, Punnonen K, Jansen C, Hemminki K: Selective deletion of exon 1 beta of the p19ARF gene in metastatic melanoma cell lines. Genes Chrom Cancer 23:273-277, 1998
46. Kunisada T, Lu SZ, Yoshida H et al: Murine cutaneous mastocytosis and epidermal melanocytosis induced by keratinocyte expression of transgenic stem cell factor. J Exp Med 187:1565-1573, 1998
47. Lyman S, Jacobsen S: c-kit ligand and Flt3 ligand: Stem/progenitor cell factors with overlapping yet distinct activities. Blood 91:1101-1134, 1998
48. Maehama T, Dixon JE: PTEN: A tumour suppressor that functions as a phospholipid phosphatase. Trends Cell Biol 9:125-128, 1999
49. Mintz B, Silvers WK: Transgenic mouse model of malignant skin melanoma. Proc Natl Acad Sci USA 90:8817-8821, 1993
50. Mitra J, Dai C, Somasundaram K, El-Deiry W, Satyamoorthy K, Herlyn M, Enders G: Induction of p21 (WAF1/CIP1) and inhibition of Cdk2 mediated by tumor suppressor p16 (INK4A). Mol Cell Biol 19:3916-3928, 1999
51. Mulligan LM, Kwok JB, Healey CS, et al: Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 336:458-460, 1993
52. Noonan FP, Otsuka T, Bang S, Anver M, Merlino G: Accelerated ultraviolet radiation-induced carcinogenesis in hepatocyte growth factor/scatter factor transgenic mice. Cancer Res 60:3738-3743, 2000
53. Noonan F, Recio J, Takayama H, et al: Neonatal sunburn and melanoma in mice. Nature 413:271-272, 2001
54. Otsuka T, Takayama H, Sharp R, et al: c-Met autocrine activation induces development of malignant melanoma and acquisition of the metastatic phenotype. Cancer Res 58:5157-5167, 1998
55. Paramio JM, Navarro M, Segrelles C, Gomez-Casero E, Jorcano JL: PTEN tumour suppressor is linked to the cell cycle control through the retinoblastoma protein. Oncogene 18:7462-7468, 1999
56. Penna D, Schmidt A, Beermann F: Tumors of the retinal pigment epithelium metastasise to the inguinal lymph nodes and spleen in tyrosinase-related protein 1/SV40 T antigen transgenic mice. Oncogene 17:2601-2607, 1998
57. Petronzelli F, Sollima D, Coppola G, Martini-Neri ME, Neri G, Genuardi M: CDKN2A germline splicing mutation affecting both p16 (ink4) and p14 (arf) RNA processing in a melanoma/neurofibroma kindred. Genes Chromosom Cancer 31:398-401, 2001
58. Platz A, Hansson J, Ringborg U: Screening of germline mutations in the CDK4, CDKN2C and TP53 genes in familial melanoma: A clinic-based population study. Int J Cancer 78:13-15, 1998
59. Podsypanina K, Ellensen L, Nemes A, et al: Mutations of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci USA 96:1563-1568, 1999
60. Pollock P, Trent J: The, genetics, of, cutaneous, melanoma. Clin Lab Med 20:667-690, 2000
61. Pollock P, Walker G, Glendening M, Que Noy T, Bloch N, Fountain J, Hayward N: PTEN inactivation is rare in melanoma tumours but occurs frequently in melanoma cell lines. Melanoma Res, in press, 2002
62. Quevedo W, Fleischmann R: Developmental biology of mammalian melanocytes. J Invest Dermatol 75:116-120, 1980
63. Randerson-Moor JA, Harland M, Williams S, et al: A germline deletion of p14 (ARF) but not CDKN2A in a melanoma-neural system tumour syndrome family. Hum Mol Genet 10:55-62, 2001
64. Rane S, Dubus P, Mettus R, Galbreath E, Boden G, Reddy E, Barbacid M: Loss of CDK4 expression causes insulin-deficient diabetes and CDK4 activation results in b-islet cell hyperplasia. Nature Genet 22:44-52, 1999
65. Recio JA, Merlino G: Hepatocyte growth factor/scatter factor activates proliferation in melanoma cells through p38 MAPK, ATF-2 and cyclin D1. Oncogene 21:1000-1008, 2002
66. Rizos H, Puig S, Badenas C, et al: A melanoma-associated germline mutation in exon 1b inactivates p14ARF. Oncogene 20:5543-5547, 2001b
67. Schmidt A, Tief K, Yavuzer U, Beermann F: Ectopic expression of ret results in microphthalmia and tumors of the retinal pigment epithelium. Int J Cancer 80:600-605, 1999
68. Schmidt EE, Ichimura K, Reifenberger G, Collins VP: CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res 54:6321, 1994
69. Schmidt L, Duh FM, Chen F, et al: Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 16:68-73, 1997
70. Sears R, Nevins J: Signalling networks that link cell proliferation and cell fate. J Biol Chem 277:11617-11620, 2002
71. Serrano M, Lee H-W, Chin L, Cordon-Cardo C, Beach D, DePinho R: Role of INK4a locus in tumour suppression and cell mortality. Cell 85:27-37, 1996
72. Arf predisposes mice to tumorigenesis. Nature 413:86-91, 2001
73. Sherr C, Roberts J: CDK inhibitors. Positive and negative regulators of G1-S phase progression. Genes Dev 13:1501-1512, 1999
74. Silvers WK, Mintz B: Differences in latency and inducibility of mouse skin melanomas depending on the age and anatomic site of the skin. Cancer Res 58:630-632, 1998
75. Sotillo R, Dubus P, Martin J, de la Cueva E, Ortega S, Malumbres M, Barbacid M: Wide spectrum of tumours in knock-in mice carrying a Cdk4 protein insensitive to INK4 inhibitors. EBMO J 20:6637-6647, 2001a
76. Sotillo R, Garcia J, Ortega S, Martin J, Dubus P, Barbacid M, Malumbres M: Invasive melanoma in Cdk4-targeted mice. Proc Natl Acad Sci USA 98:13312-13317, 2001b
77. Soufir N, Avril MF, Chompret A, et al: Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. Hum Mol Genet 7:209-216, 1998
78. Sviderskaya EV, Hill SP, Evans-Whipp TJ et al: p16 (Ink4a) in melanocyte senescence and differantiation. J Natl Cancer Inst. 94(6):446-454, 2002
79. Takahashi M, Iwamoto T, Nakashima I: Proliferation and neoplastic transformation of pigment cells in metallothionein/ret transgenic mice. Pigment Cell Res 5:(2)344-347, 1992
80. Takayama H, LaRochelle W, Anver M, Bockman D, Merlino G: Scatter factor/hepatocyte growth factor as a regulator of skeletal muscle and neural crest development. Proc Natl Acad Sci USA 93:5866-5871, 1996
81. Tang L, Li L, Tron V, Trotter M, Ho V: Expression of cell cycle regulators in human cutaneous malignant melanoma. Melanoma Res 9:148-154, 1999
82. Tolkacheva T, Chan AM: Inhibition of H-Ras transformation by the PTEN/MMAC1/TEP1 tumor suppressor gene. Oncogene 19:680-689, 2000
83. Tsao H, Benoit E, Sober AJ, Thiele C, Haluska FG: Novel mutations in the p16/CDKN2A binding region of the cyclin dependent kinase-4 gene. Cancer Res 58:109-112, 1998
84. Tsao H, Zhang X, Fowlkes K, Haluska FG: Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines. Cancer Res 60:1800-1804, 2000
85. Van Elsas A, Zerp SF, Van der Fliers S: et al: Relevance of ultraviolet-induced N-ras oncogene point mutations in development of primary cutaneous melanoma. Am J Pathol 149:883-893, 1996
86. Van Weering D, Bos J: Signal transduction by the receptor tyrosine kinase Ret. Recent Results Cancer Res 154:271-281, 1998
87. Walker GJ, Flores JF, Glendening JM, Lin AH, Markl ID, Fountain JW: Virtually 100% of melanoma cell lines harbor alterations at the DNA level within CDKN2A, CDKN2B, or one of their downstream targets. Genes Chrom Cancer 22:157-163, 1998
88. Walker GJ, Hayward NK: No evidence of a role for activating CDK2 mutations in melanoma. Melanoma Res 11:343-348, 2001
89. Wellbrock C, Gomez A, Schartl M: Signal transduction by melanoma oncogenic receptor tyrosine kinase Xmrk in melanoma formation of Xiphophorus. Pigment Cell Res 10:34-40, 1997
90. Weng LP, Brown JL, Eng C: PTEN coordinates G(1) arrest by down-regulating cyclin D1 via its protein phosphatase activity and up-regulating p27 via its lipid phosphatase activity in a breast cancer model. Hum Mol Genet 10:599-604, 2001
91. Whiteman D, Whiteman C, Green A: Childhood sun exposure as a risk factor for melanoma. A systematic review of epidemiological studies. Cancer Causes Control 12:69-82, 2001
92. Xiao Z, Chen J, Levine A, Modjtahedi N, Xing J, Sellers W, Livingston D: Interactions between the retinoblastoma protein and the oncoprotein mdm2. Nature 375:694-697, 1995
93. You MJ, Castrillon DH, Bastian BC, et al: Genetic analysis of Pten and Ink4a/Arf interactions in the suppression of tumorigenesis in mice. Proc Natl Acad Sci USA 99:1455-1460, 2002
94. Zhang Y, Xiong Y, Yarbrough WG: ARF promotes mdm2 degradation and stabilizes p53; ARF-INK4a locus deletion impairs both Rb and p53 tumour suppression pathways. Cell 92:725-734, 1998
95. Zhu H, Reuhl K, Zhang X, Botha R, Ryan K, Wei J, Chen S: Development of heritable melanoma in transgenic mice. J Invest Dermatol 110:247-252, 1998
96. Zuo L, Weger J, Yang Q, et al: Germline mutations of the p16 binding domain of CDK4 in familial melanoma. Nat Genet 12:97-99, 1996